Kymera Therapeutics (KYMR) Treasury Shares (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Treasury Shares data on file, last reported at $1.5 million in Q1 2026.

• Treasury Shares for Q1 2026 came in at $1.5 million, up 26.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 million (up 26.88% YoY), and the FY2025 annual result was $1.3 million, up 79.45% from the prior year.
• Treasury Shares climbed to $1.5 million in Q1 2026 per KYMR's latest filing, from $1.3 million in the prior quarter.
• Over five years, Treasury Shares peaked at $1.5 million in Q1 2026 and troughed at $121504.0 in Q1 2022.
• A 5-year average of $746263.2 and a median of $636585.0 in 2024 frame the typical range for Treasury Shares.
• The sharpest annual moves came in 2022 and 2024: Treasury Shares surged 646.7% in 2022, then rose 26.38% in 2024.
• A 5-year view of Treasury Shares shows it stood at $281843.0 in 2022, then soared by 110.45% to $593140.0 in 2023, then increased by 26.38% to $749604.0 in 2024, then surged by 79.45% to $1.3 million in 2025, then gained by 14.13% to $1.5 million in 2026.
• Business Quant data shows KYMR's Treasury Shares at $1.5 million in Q1 2026, $1.3 million in Q4 2025, and $1.4 million in Q3 2025.